Neurodegenerative Disease Management

metrics 2024

Elevating Standards in Neurodegenerative Disease Research

Introduction

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

Metrics 2024

SCIMAGO Journal Rank0.62
Journal Impact Factor2.30
Journal Impact Factor (5 years)2.60
H-Index32
Journal IF Without Self2.30
Eigen Factor0.00
Normal Eigen Factor0.18
Influence0.61
Immediacy Index0.60
Cited Half Life6.10
Citing Half Life7.50
JCI0.59
Total Documents411
WOS Total Citations865
SCIMAGO Total Citations2044
SCIMAGO SELF Citations28
Scopus Journal Rank0.62
Cites / Document (2 Years)2.59
Cites / Document (3 Years)2.45
Cites / Document (4 Years)2.74

Metrics History

Rank 2024

Scopus

Neurology (clinical) in Medicine
Rank #180/400
Percentile 55.00
Quartile Q2

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 146/277
Percentile 47.50
Quartile Q3

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 176/278
Percentile 36.69
Quartile Q3

Quartile History

Similar Journals

Journal of Neurologic Physical Therapy

Empowering Practitioners in Neurologic Physical Therapy
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1557-0576Frequency: 4 issues/year

Journal of Neurologic Physical Therapy, published by Lippincott Williams & Wilkins, stands as a premier resource in the field of physical therapy with a specific focus on neurology. With an ISSN of 1557-0576 and an E-ISSN of 1557-0584, this journal serves as a vital platform for researchers, practitioners, and students from 2004 to 2024, illustrating its commitment to advancing knowledge in neurologic rehabilitation. It holds a prestigious Q1 ranking in categories such as Physical Therapy, Sports Therapy, and Rehabilitation and Rehabilitation, alongside Q2 rankings in Geriatrics and Gerontology, Medicine (Miscellaneous), and Neurology (Clinical). With an impact factor that reflects its significance, the journal hosts comprehensive studies and clinical insights that propel practice and innovation in neurologic physical therapy. The content is designed to enhance understanding and skills, making it an indispensable resource for those dedicated to improving patient care and outcomes in this critical area of health.

Alzheimers Research & Therapy

Connecting researchers to transform Alzheimer's understanding.
Publisher: BMCISSN: Frequency: 1 issue/year

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

EUROPEAN JOURNAL OF NEUROLOGY

Pioneering Research at the Forefront of Neurology.
Publisher: WILEYISSN: 1351-5101Frequency: 12 issues/year

EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

JAMA Neurology

Empowering Clinicians with Cutting-Edge Neurological Knowledge
Publisher: AMER MEDICAL ASSOCISSN: 2168-6149Frequency: 12 issues/year

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Turkish Journal of Neurology

Exploring the frontiers of neurology in Turkey and beyond.
Publisher: GALENOS PUBL HOUSEISSN: 1301-062XFrequency: 4 issues/year

Turkish Journal of Neurology, published by GALENOS PUBL HOUSE, is a pivotal open-access journal established in 2004, dedicated to advancing the field of neurology. Renowned for its inclusive approach, this journal serves as a vital platform for researchers and clinicians to share their findings and insights related to neurological disorders and clinical practices, with an emphasis on enhancing the understanding of various neurological conditions affecting populations in Turkey and beyond. Although it holds a Q4 rank in Neurology (Clinical) as per the 2023 category quartiles, the journal's commitment to fostering knowledge exchange remains steadfast, aiming to bridge gaps in clinical research and practice. With an ISSN of 1301-062X and an E-ISSN of 1309-2545, it is indexed in Scopus, ranking 349 out of 400, reflecting its growing presence in the academic sphere. Located in Istanbul, Turkey, the journal invites submissions from both emerging and established researchers to contribute to its diverse content, thereby enhancing its impact on the local and international neurology community.

Journal of Parkinsons Disease

Fostering collaboration to illuminate Parkinson's research.
Publisher: IOS PRESSISSN: 1877-7171Frequency: 8 issues/year

The Journal of Parkinson's Disease, published by IOS PRESS, is a premier open-access journal dedicated to advancing the understanding of Parkinson's Disease and related disorders. Established in 2011, the journal has swiftly gained recognition, achieving impressive rankings within its field: it ranks Q1 in Neurology (clinical) and Q2 in Cellular and Molecular Neuroscience as of 2023. With an impact factor indicative of its rigorous peer-review process and scholarly contribution, the journal stands at the forefront of medical research, particularly positioned within the top 15% of clinical neurology journals worldwide. The journal's open access since 2023 ensures that vital research is readily available to the global scientific community, facilitating knowledge exchange and collaboration. Covering a broad spectrum of topics from basic molecular mechanisms to clinical treatments, the Journal of Parkinson's Disease serves as an essential resource for researchers, clinicians, and students dedicated to tackling one of the most challenging neurodegenerative conditions.

Current Neuropharmacology

Pioneering insights in brain health and pharmacology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

NEUROLOGY

Exploring breakthroughs in neurological research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0028-3878Frequency: 48 issues/year

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

Journal of Central Nervous System Disease

Exploring the frontiers of neuroscience.
Publisher: SAGE PUBLICATIONS LTDISSN: 1179-5735Frequency: 1 issue/year

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

ACTA NEUROLOGICA SCANDINAVICA

Advancing Neurological Insights
Publisher: WILEYISSN: 0001-6314Frequency: 12 issues/year

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.